High-dose CBD (800 mg/day) Reduces Neuropathic Pain After Spinal Cord Injury — Phase 2 Double‑Blind Trial Successful

A Phase 2 double‑blind, randomized crossover trial conducted in Sydney, Australia found that high‑dose cannabidiol (CBD; 800 mg/day) produced a statistically significant reduction in neuropathic pain in people with spinal cord injury. Safety and tolerability were confirmed, supporting the rationale for larger‑scale clinical trials.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.